Myomegalin is a novel protein of the Golgi/centrosome that interacts with a cyclic nucleotide phosphodiesterase by Verde, Ignacio et al.
Myomegalin Is a Novel Protein of the Golgi/Centrosome That
Interacts with a Cyclic Nucleotide Phosphodiesterase*
Received for publication, July 21, 2000, and in revised form, December 6, 2000
Published, JBC Papers in Press, December 27, 2000, DOI 10.1074/jbc.M006546200
Ignacio Verde‡§, Gudrun Pahlke‡§, Michele Salanova‡, Gu Zhang‡, Sonya Wang‡, Dario Coletti‡,
James Onuffer¶, S.-L. Catherine Jin‡, and Marco Conti‡i
From the ‡Division of Reproductive Biology, Department of Gynecology and Obstetrics, Stanford University School of
Medicine, Stanford, California 94305-5317 and the ¶Department of Immunology, Berlex Biosciences,
Richmond, California 94804-0099
Subcellular targeting of the components of the cAMP-
dependent pathway is thought to be essential for intra-
cellular signaling. Here we have identified a novel pro-
tein, named myomegalin, that interacts with the cyclic
nucleotide phosphodiesterase PDE4D, thereby target-
ing it to particulate structures. Myomegalin is a large
2,324-amino acid protein mostly composed of a-helical
and coiled-coil structures, with domains shared with
microtubule-associated proteins, and a leucine zipper
identical to that found in the Drosophila centrosomin.
Transcripts of 7.5–8 kilobases were present in most tis-
sues, whereas a short mRNA of 2.4 kilobases was de-
tected only in rat testis. A third splicing variant was
expressed predominantly in rat heart. Antibodies
against the deduced sequence recognized particulate
myomegalin proteins of 62 kDa in testis and 230–250 kDa
in heart and skeletal muscle. Immunocytochemistry and
transfection studies demonstrate colocalization of
PDE4D and myomegalin in the Golgi/centrosomal area
of cultured cells, and in sarcomeric structures of skele-
tal muscle. Myomegalin expressed in COS-7 cells coim-
munoprecipitated with PDE4D3 and sequestered it to
particulate structures. These findings indicate that
myomegalin is a novel protein that functions as an an-
chor to localize components of the cAMP-dependent
pathway to the Golgi/centrosomal region of the cell.
Only in recent years has it been realized that the components
of the signal transduction machinery are organized in macro-
molecular complexes located in close proximity to the plasma
membrane or in discrete subcellular structures. These com-
plexes are assembled by scaffold proteins often devoid of enzy-
matic activity and for the sole function of bringing together
different signaling molecules (1, 2). These signaling/scaffold
protein complexes are necessary and often indispensable for
signaling, as disruption or blocking the formation of these
complexes decreases the efficiency of signaling or negates it
altogether.
Even though cAMP is a diffusible second messenger, the
enzymes involved in this signaling pathway are targeted to
different subcellular compartments. With few exceptions, ad-
enylyl cyclases are plasma membrane-associated proteins, and
protein kinase A (PKA),1 one of the effectors of cAMP signaling,
is anchored to discrete structures within the cell via regulatory
subunit interaction with A kinase anchoring proteins (AKAPs)
(3, 4). Several different AKAPs that function as scaffold pro-
teins have been characterized. For instance, AKAP79 is part of
a multicomplex, which, in addition to the PKA regulatory sub-
unit RII, includes protein kinase C and the phosphatase PP2B/
calcineurin (5). Disruption of the PKA interaction with AKAPs
abolishes the cAMP-dependent regulation of ion channels (6,
7). PKA regulatory subunits have also been localized in the
centrosome in culture cells (8), and in cells of the central
nervous system (9), thus opening the possibility that microen-
vironments of cAMP signaling may be necessary for intracel-
lular trafficking and organelle movements during cell
replication.
Cyclic nucleotide phosphodiesterases, the enzymes that de-
grade and inactivate cAMP, may play an important role in
signaling compartmentalization by controlling cAMP diffusion
to reach the PKA isoenzymes anchored to different organelles.
Of the wide array of PDE isoforms present in a cell (10–13),
several are recovered in the particulate fraction of the homo-
genate and have been immunolocalized to different cellular
compartments. We and others have shown that variants de-
rived from the PDE4D gene are particulate or soluble, depend-
ing on the amino terminus present in the protein (14–16), and
are located in different subcellular compartments as shown by
immunofluorescence studies. In FRTL-5 thyroid cells, two vari-
ants (PDE4D3 and PDE4D4) with long amino termini are
recovered in the particulate fraction, and are localized in a
perinuclear region corresponding to centrosomal inner/Golgi
structures, as well as to the membrane cortical region (16).
Conversely, a third variant (PDE4D2), the expression of which
is cAMP-dependent, is recovered mostly in the soluble fraction
and its induction by cAMP is associated with diffuse immun-
ofluorescent signals in these cells (16). Localization of PDE4D
in discrete subcellular structures has also been demonstrated
in macrophages (17). These findings open the possibility that
the subcellular localization of PDE4D is finely controlled and
this localization may be dynamically regulated during cAMP
signaling.
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To understand the mechanism of PDE4 subcellular target-
ing, we sought to identify proteins that interact with these
PDE4D variants and to anchor them to different organelles.
Here we describe the properties of a novel protein named
myomegalin, which is a major component of skeletal and car-
diac muscle but is expressed at low levels in all cells studied.
Although in nonmuscle cells it is targeted to the Golgi/centro-
somal region, myomegalin localizes in the sarcomeres in heart
and skeletal muscle. This protein colocalizes with PDE4D in
the cells and tissue studied.
EXPERIMENTAL PROCEDURES
Yeast Strains and Growth Conditions—The yeast strains of Saccha-
romyces cerevisiae (Y190, HF7c, Y187), cloning vectors, and the activat-
ing domain (AD) rat brain cDNA library used for the yeast two-hybrid
screening (Matchmaker I and II) as well as the lgt11 cDNA libraries
(from rat brain and rat skeletal muscle) were obtained from CLON-
TECH (Palo Alto, CA), yeast media from Difco (Detroit, MI), and amino
acids and 3-amino-1,2,4,-triazole (3-AT) from Sigma. Restriction en-
zymes were purchased from Roche Molecular Biochemicals, DNA mod-
ifying enzymes and PCR reagents from Life Technologies, Inc. or Strat-
agene (La Jolla, CA).
The yeast strain Y190 of S. cerevisiae was used as host for the yeast
two-hybrid screening, whereas HF7c and Y187 were used for mating
experiments. Yeast transformation was performed using the lithium
acetate method according to Gietz et al. (47). Single transformants were
spread on selection medium (SD medium) lacking Leu or Trp. Cotrans-
formants of strain Y190 were propagated on SD medium containing Ade
(10 mg/ml) and 50 mM 3-AT. Single transformants of Y187 were grown
on SD medium lacking Trp. The yeast strain HF7c was transformed
with Gal4 activation domain expressing His1Z1 clones from the li-
brary screen. Transformants were propagated on SD/2Leu.
Yeast Two-hybrid Screening of a Brain cDNA Library—The yeast
strain Y190 was used to screen a rat brain Gal4/AD library to identify
genes encoding proteins that interact with ratPDE4D3. The amino
terminus (aa 1–133) of PDE4D3 as well as a truncated form of
ratPDE4D3 that included the autoinhibitory (UCR2), catalytic, and
COOH-terminal domain (aa 134–end of rPDE4D3) were used as a bait.
The cDNA corresponding to the truncated PDE (base 400–2018 of the
PDE4D3 ORF, accession no. U09457) was amplified by PCR using the
full-length ratPDE4D3 cDNA as a template. The following primers with
incorporated restriction sites were used: GUPA4, EcoRI 59-CGGAAT-
TCGAGGAGGCCTACCAGAAAC-39; and GUPA3, 59-TGAGTCGAC-
TACGTGTCAGGACAACAATCGTC-39 SalI. The PCR product was sub-
cloned into the EcoRI/SalI site of pGBT9 downstream from the Gal4
DNA binding domain (plasmid pGBT9/1.6). Amplifications were per-
formed in the presence of recombinant Pfu polymerase at a low cycle
number to ensure high fidelity amplification. The amplified fragment
was sequenced in its entire length to confirm the correct reading frame
and sequence. Sequencing was performed by Stanford University facil-
ities using the ABI PRISM Dye Terminator Cycle Sequencing Ready
Reaction kit with AmpliTaq DNA polymerase, FS (PerkinElmer Life
Sciences). Further truncations of ratPDE4D3 were obtained as reported
previously (18) to identify the PDE domain responsible for the interac-
tion with positive AD/library clones. These included PDEtruA (aa 164–
end), PDEtruB (aa 179–end), and PDEtruC (214–end). The construc-
tion of the plasmid containing the amino terminus of PDE4D3 (0.4) has
been described previously (18). Under the experimental conditions
used, the full-length PDE4D3 (93 kDa) did not express well as a fusion
protein in yeast nuclei.
A portion of the AD/cDNA plasmid library was amplified once to
obtain sufficient plasmid DNA for screening. The plasmid DNAs of bait
and library (concentration ratio 2:1) were simultaneously transformed
into Y190 cells on a large scale basis according to the manufacturer’s
protocol. Protein expression in Y190 was induced on SD/Ade, 50 mM
3-AT (6.7 g/liter yeast nitrogen base without amino acids, pH 5.8; 18
g/liter agar, 10 mg/liter adenine, 2% dextrose, and 50 mM 3-amino-1,2,4-
triazole). Transcriptional autoactivation of the pGBT9/1.6 was moni-
tored by single and cotransformation with control plasmids containing
the Gal4 transcriptional activation domain alone (pGAD10) or with
other in frame cDNAs such as the SV40 large T-antigene (pTD1) and
pGAD10/1.6. No background for b-galactosidase activity was detected
after overnight incubation at 30 °C.
After 7–19 days of incubation at 30 °C, the colonies growing on His1
plates were counted and patched onto fresh SD/Ade, 50 mM 3-AT,
together with controls. The first group of patched His1 clones was
checked again for positive growth 5 days after incubation. At that stage,
a b-galactosidase filter lift assay was carried out to detect positive
clones. Each His1Z1 clone was restreaked on SD/Ade, 50 mM 3-AT
medium to generate single clones. Single colonies were reassayed for
b-galactosidase activity. The clones obtained by screening with the
amino terminus of PDE4D3 will be reported elsewhere.
To isolate Leu1Trp1 yeast segregants with only the AD/library
plasmid, His1Z1 transformants were cultured in YPD medium over-
night at 30 °C. An aliquot of the sample was spread on SD/2Leu and
incubated for 3 days. Colonies were replica-plated on SD/2Leu only and
on SD/2Leu,2Trp plates. Colonies growing on SD/2Leu plates (1Trp)
but not on SD/2Leu,2Trp (2Trp) carry the AD/library plasmid; how-
ever, the plasmid containing the bait had been lost. These Trp aux-
otrophs were reassayed for b-galactosidase activity. Negative clones
were saved. Plasmid DNA was isolated from Trp auxotrophs according
to the manufacturer’s protocol and was used for transformation into E.
coli strain HB101 using electroporation (Genepulser, Bio-Rad).
To confirm the interaction of the isolated clones with the bait, yeast
strain Y190 and HF7c were retransformed with bait and AD/library
plasmid and tested for yeast mating and for b-galactosidase expression.
To measure the b-galactosidase activity in transformants, the colony
lift filter assay was done according to the manufacturer’s protocol
(CLONTECH). Blue colonies were developed after incubation overnight
at 30 °C.
Yeast Mating—Yeast strain Y187 was transformed with pGBT9 and
pGBT9/1.6 and selected for Trp1 transformants. Yeast strain HF7c was
single transformed with pGAD10, pGAD10/library positive clones.
Transformants were propagated on SD/2Leu. Individual positive colo-
nies for Trp and Leu were streaked separately on the corresponding SD
medium and grown for 3–4 days at 30 °C. The different transformants
of Trp1 and Leu1 were replica-plated in a grid pattern on YPD plates
and incubated overnight at 30 °C. Colonies of diploid cells were replica-
plated on SD medium lacking Leu, Trp, and His. After ;6 days, His1
colonies were counted and LacZ expression was detected using the
b-galactosidase assay.
Cloning by Library Screening—To obtain the complete sequence of
the PDE4D3-interacting protein myomegalin, the PBP46 cDNA iso-
lated from the yeast library screening was used as a probe to screen rat
brain and skeletal muscle lgt11 libraries (CLONTECH). Three of the
more than 50 clones retrieved were sequenced, and the overlap with
PBP46 was established by multiple sequence alignment. Because the
potential initiation codon was absent in all three clones, oligonucleo-
tides corresponding to the 59 end of the new open reading frame were
designed and used for further screening of the same library. This
procedure was repeated four times until a clone containing in-frame
stop codons upstream from the putative initiation codon was retrieved.
Overlapping cDNAs were used to reconstruct the entire open reading
frame of myomegalin. Melds were confirmed by at least two overlapping
clones. Three of the clones retrieved contained 59 ends that could not be
aligned with the reconstructed open reading frame. Whether these
clones encompass splicing junctions or are cloning artifacts was not
further investigated.
Northern Blot Analysis—Two different DNA probes (probe 1, 1000
bp; probe 2, 665 bp) derived from the ORF of myomegalin were labeled
with [a-32P]dCTP by the random primer procedure (Life Technologies,
Inc.). The labeled probes were purified using Quick Spin G-25 Sephadex
columns (Roche Molecular Biochemicals) and used to hybridize a rat
multiple tissue Northern blot (CLONTECH). Hybridization and wash-
ing procedures were carried out according to the manufacturer’s
protocol.
RT-PCR Analysis—Poly(A1) mRNA was isolated from rat heart and
skeletal muscle using the QuickPrep Micro mRNA purification kit
(Amersham Pharmacia Biotech). First strand cDNA was prepared from
mRNA with random hexanucleotide primers (20 pmol/mg of RNA) using
murine reverse transcriptase and the conditions recommended by the
manufacturer’s protocol (Amersham Pharmacia Biotech). The cDNA
obtained was amplified with the following oligonucleotide primers de-
signed against different regions of myomegalin: MYO1-MYO2, forward
primer (59-GTGGAGAGCCTGAAAACGAGAG-39, corresponding to
bases 163–183 (aa 55–61)) and reverse primer (59-AGTCGTCTCA-
GAAGCAAGATACGA-39, corresponding to bases 830–844 (aa 274–
282); predicted fragment, size 682 bp); MYO3-MYO4, forward primer
(59-GAAGCTAGCTCTCCCCGCTACA-39, corresponding to bases 5266–
5287 (aa 1756–1764)) and reverse primer (59-CTACGAGTCCCTCTAC-
GAAAAT-39, corresponding to bases 5987–6009 (aa 1995–2003; pre-
dicted fragment size, 743 bp)); KIA1-MYO2, forward primer (59-
CTGTGGAATCTTTGGATGCAAGCGT-39, bp 1379–1403 of KIAA0477)
and reverse primer (59-AGTCGTCTCAGAAGCAAGATACGA-39, frag-
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ment size, 587 bp). Thirty cycles of PCR amplification were usually used
(60 s at 94 °C, 60 s at 50 °C, and 2 min at 72 °C) and a final elongation
(10 min at 72 °C). The PCR products were separated on 1% agarose gel
containing 0.01% ethidium bromide and photographed under UV irra-
diation at 320 nm.
Antibody Generation—The peptide PBP4 (FASGHGRHVIGHVDDY-
DALQQQI) was conjugated to keyhole limpet hemocyanin for immuni-
zations in rabbits. The immunizations and bleeds were performed at
Strategic BioSolutions, Inc. (Ramona, CA). For affinity purification, the
PBP4 peptide was immobilized to 3 M Emphazey Biosupport Medium
AB 1 using the Ultralinky immobilized carboxy kit from Pierce. The
PBP4-specific IgG was eluted from the column by sequential washes at
low pH (ImmunoPure IgG elution buffer, Pierce) and at high pH (0.1 M
triethylamine, pH 11.5). The antibodies were buffer exchanged to PBS
and concentrated to 1 mg/ml using an Ultrafree-15 Biomax-30 centrif-
ugal filter device (Millipore Corp., Bedford, MA).
Western Blot Analysis—Tissues or cells were homogenized in a
Dounce homogenizer using a hypotonic buffer consisting of 20 mM Tris,
pH 8.0, 1 mM EDTA, 0.2 mM EGTA, 50 mM NaF, 10 mM sodium
pyrophosphate, 50 mM benzamidine, 0.5 mg/m leupeptin, 0.7 mg/ml
pepstatin, 4 mg/ml aprotinin, 10 mg/ml soybean trypsin inhibitor, 1 mM
microcystine, and 1 mg/ml phenylmethylsulfonyl fluoride (homogeniza-
tion buffer). After homogenization the extract was centrifuged for 40
min at 14,000 3 g to separate soluble and particulate fractions. Both
fractions were diluted in 13 sample buffer (62.5 mM Tris, pH 6.8, 10%
glycerol, 2% (w/v) SDS, 0.7 mM b-mercaptoethanol, and 0.0025% (w/v)
bromphenol blue), boiled for 5 min, and subjected to electrophoresis on
8% SDS-polyacrylamide gel. The proteins were then blotted onto an
Immobilon membrane (Bio-Rad), followed by blocking of the membrane
in TBS-T (20 mM Tris-HCl, pH 7.6, 14 mM NaCl, 0.1% Tween 20)
containing 0.1% (w/v) nonfat milk. After several washes, the membrane
was incubated with the primary antibody (M3S1, PBP4 antiserum, or
anti-flag tag antibody) in TBS-T for 60 min, then washed with TBS-T
followed by another 1-h incubation with peroxidase-linked anti-rabbit
or anti-mouse IgG. After several washes with TBS-T, the membrane
was incubated with the ECL detection reagent (Amersham Pharmacia
Biotech) and exposed to XAR-5 x-ray film for 5–120 s (Eastman Kodak
Co.) to detect the peroxidase-conjugated secondary antibodies.
Freshly excised skeletal and heart tissue was frozen in liquid nitro-
gen. After pulverization, the tissue was extracted with buffer contain-
ing 5 mM EGTA, 7 mM ATP, 130 mM propionic acid, 5 mM imidazole, 10
mM MOPS, pH 7.2, and a mixture of protease inhibitors, following the
method of Brandt et al. (20). After homogenization with all glass ho-
mogenizer, the samples were centrifuged at 100,000 3 g. The pellets
were extracted with 13 sample buffer and centrifuged at 14,000 3 g to
remove particulate material. After dilution in sample buffer, superna-
tants and pellets were fractionated by SDS-PAGE as above.
Transfection and Immunofluorescence Localization—The truncated
myomegalin (63 kDa) was tagged with flag epitope (DYKDDDDK) at its
NH2 terminus by transferring the insert PBP46 to the BamHI/BglII of
a modified vector (gift of Dr. Louis Naumovsky, Stanford University,
Stanford, CA) derived from pCEP4 (Invitrogen Corp., Carlsbad, CA).
The construct was transfected in COS-7 cells using the calcium phos-
phate method (19). Cells were grown in Eagle’s medium (Life Technol-
ogies) for 48 h, fixed with ethanol-acetone solution (1:1) for 10 min,
preincubated with PBS containing 0.1% bovine serum albumin for 20
min, and then incubated with specific primary antibodies in PBS for
1 h. Rabbit polyclonal PBP4 antibody was used at 1:100 dilution,
anti-flag at 1:80, CTR433 (median Golgi marker) (21) at 1:10, CTR453
(centrosomal marker) (22) at 1:500, and M3S1 at 1:50. After the cells
were washed with PBS three times, fluorescent fluorescein isothiocya-
nate- or rhodamine-conjugated secondary antibodies (1:100 dilution;
Vector Laboratories, Inc., Burlingame, CA) were then added to the cells.
The expressed proteins were localized using fluorescence microscopy
after mounting the samples with Vectashield mounting medium (Vector
Laboratories, Inc.). Tissue immunofluorescence localization was per-
formed according to previously published methods (23).
PDE Assay—PDE activity was measured with 1 mM cAMP as sub-
strate according to the method of Thompson and Appleman (24) with
minor modification (16). Protein concentrations of the samples were
measured according to the method of Bradford (25).
RESULTS
Isolation of Clones Coding for Proteins That Interact with
PDE4D in the Yeast Two-hybrid Screen—A yeast two-hybrid
screening of a rat brain library with baits corresponding to
amino acids 1–133 and 134–end of PDE4D3 (see Fig. 1) yielded
several clones that interacted strongly with the PDE in both
the b-galactosidase and yeast growth assays. Of these positive
clones, one (PBP46) was further characterized because the
sequence of this cDNA demonstrated only weak similarity with
known sequences. The interaction with the PDE was evident
whether the cDNA was fused to the activation or the DNA
binding domain, and when either a growth or b-galactosidase
assay was used (Fig. 1). Analysis using constructs containing
the different PDE4D domains indicated that PBP46 interacted
with the amino terminus of PDE4D in a region that corre-
sponds to the upstream conserved region 2 (UCR2) of PDE4 (aa
134–164 of PDE4D3) (Fig. 1). This conclusion is based on the
observation that constructs encoding aa 1–133 (0.4), aa 164–
end (TruA), 179–end (TruB), and 214–end (TruC) of PDE4D3
(Fig. 1) did not interact with PBP46. This PDE domain is
upstream from an autoinhibitory domain that controls the cat-
alytic activity of the enzyme (18).
Cloning of the Full-length cDNA Coding for Myomegalin—
Northern blot analysis with mRNAs from different rat tissues
indicated that PBP46 cDNA corresponds to a gene that is
expressed at a high level in skeletal muscle and heart (see
below). A rat skeletal muscle lgt11 cDNA library was therefore
repeatedly screened using the PBP46 cDNA as a probe. To
obtain the entire ORF, the library was screened four times and
18 overlapping clones were characterized. A meld of these
clones indicated the presence of an uninterrupted ORF of 6975
bp, which encodes a protein of 2324 amino acids with a calcu-
lated molecular mass of 262 kDa (Fig. 2). An additional 1000 bp
of 39-UTR and more than 500 bp of 59-UTR are consistent with
the 7.5–8-kb transcript detected by Northern blot analysis (see
below). In view of the high level of expression in muscle cells
and the large size of the encoded protein, this new gene was
termed myomegalin (mmg, accession no. AF139185).
Myomegalin Structure—A computer-assisted prediction of
the secondary structure of myomegalin indicated that this pro-
tein is mostly composed of coiled-coil and a-helical domains
(Fig. 2A) with 20% identity to myosin heavy chains, even
though no sequences similar to the ATP binding domain of the
myosin heavy chain could be identified. The full-length protein
contains a putative leucine zipper at the amino terminus be-
tween residues 8 and 31 and an uncharged region rich in
proline close to the COOH-terminal region (Fig. 2, A and B).
BLAST search comparison showed that the first domain is
almost identical to the first leucine zipper of Drosophila cen-
trosomin, a protein localized in the centrosome of Drosophila
melanogaster (26). In addition, a domain between amino acids
769 and 784 is homologous to a domain of dynactin that is
responsible for the binding to the actin-like protein centractin/
ARP1. Dynactin and centractin are part of the complex impli-
cated in vesicle transport and the interaction with the micro-
tubules in mammalian cells (27). Finally, myomegalin contains
a helix-loop-helix domain between amino acids 1079 and 1094.
This domain is homologous with regions found in human CLIP-
170 (cytoplasmic linker protein) and rat DAP-150 (dynein as-
sociated polypeptide) (Fig. 2A). CLIP-170 is a protein that
binds microtubules and is implicated in the process of endocy-
tosis and organelle transport in mammalians (28). The function
of DAP-150 is still largely unknown (29). The myomegalin
domains included in the testis variant (corresponding to the
PBP46 clone, see below) contains mostly a-helices and two
coil-coil regions, as indicated in Fig. 2. The presence of coil-coil
regions and absence of putative transmembrane domains are
consistent with recovery of expressed PBP46, a truncated myo-
megalin, in particulate fractions of transfected cells, and its
resistance to solubilization with nonionic detergents alone.
Analysis of the Myomegalin Variants by Northern Blot and
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RT-PCR Analysis—To investigate whether different myomega-
lin transcripts are present in rat and to analyze their tissue
distribution, Northern blot analysis was performed using
probes corresponding to the 39 end (probe 1) and 59 end (probe
2) of the myomegalin ORF (Fig. 3A). The results indicated the
presence of abundant transcripts of ;7.5–8 kb (myomegalin-1)
in heart and skeletal muscle, which contains the entire ORF of
myomegalin (Fig. 3B). The 7.5–8-kb transcripts were also de-
tected in small amounts in brain, lung, and liver, and hybrid-
ized to both probe 1 and probe 2. Probe 1 also detected shorter
transcripts, ;5.9 kb in heart and ;2.5 kb in testis, that were
not detected with probe 2 (Fig. 3C), indicating that these tran-
scripts lack the 59 end of the coding sequence. The use of probe
2 also revealed the presence of a fourth transcript, ;4.3 kb,
present in skeletal muscle (Fig. 3C). Thus, there are at least
four different transcripts of rat myomegalin: a 7.5-kb transcript
expressed in heart and skeletal muscle, a 5.9-kb transcript in
heart, a 4.3-kb transcript in skeletal muscle, and one specific
for the testis (2.5 kb). The 2.5-kb variant, which is the shortest
form, roughly corresponds to the PBP46 clone isolated in the
yeast two-hybrid screening and is expressed exclusively in rat
testis. The presence of this shorter form was confirmed by the
isolation of two cDNA clones from a testis cDNA library (data
not shown), even though the initiation methionine of this ORF
could not be unequivocally identified. Finally, additional vari-
ants at both the 59 and 39 ends may be present on the basis of
the cDNAs retrieved (data not shown).
A BLAST search of human nucleotide expressed sequence
tag sequences indicated a high degree of conservation of rat
myomegalin and two overlapping clones identified by sequenc-
ing randomly sampled clones with insert sizes of 5–7 kb
(KIAA0477 and KIAA0454) from a human brain library (Gen-
Banky AB007946 and AB007923). The homology encompassed
most of the coding sequence except for the 59 end, again sug-
gesting the presence of splicing in the mRNA. To verify this
possibility, RT-PCR analysis was performed with mRNA from
rat heart and skeletal muscle. Different primers corresponding
to 39 (MYO3 and MYO4) and 59 end (MYO1 and MYO2) se-
quence of myomegalin, and one primer (KIA1) corresponding to
the 59 end of human sequence (Fig. 3A) were used for amplifi-
cation. This analysis indicated that transcripts expressed in
the heart and skeletal muscle most likely contain the entire
myomegalin ORF defined by cDNA cloning (Fig. 3, D and E). It
also uncovered the presence of an additional transcript contain-
ing the 59 end sequence orthologous to the human clone in
heart but not in skeletal muscle. The sequencing of the KIA1-
MYO2 PCR fragments from rat heart confirmed the presence of
a variant similar to that present in human (data not shown).
This amino terminus does not contain a leucine zipper domain.
Expression of the Myomegalin Protein—To investigate the
properties of the protein, antibodies were raised against four
peptides corresponding to the carboxyl terminus region of myo-
megalin. Of the different antisera generated, one was further
characterized (PBP4). This antibody recognized the tagged 64-
kDa myomegalin in the particulate fraction of transfected cells
(Fig. 4A). This truncated myomegalin form could not be solu-
bilized with nonionic detergent but was partially extracted
with RIPA buffer (data not shown).
Western blot analysis with the PBP4 antibody recognized
proteins of ;230–250 kDa in heart and skeletal muscle (Fig.
4B). Additional immunoreactive bands of ;150 kDa and 115
and 180 kDa were observed in heart and skeletal muscle,
respectively. Although a degradation of the 230–250-kDa spe-
cies cannot be excluded, it is possible that these additional
FIG. 1. Interaction between the carboxyl terminus region of myomegalin and PDE4D using the yeast two-hybrid assay. The PBP46
construct corresponds to amino acid 1765 to 2324 of myomegalin. The PDE4D construct used (PDE1.6) contains the inhibitory domain, the catalytic
domain, and the carboxyl-terminal domain. The PDE constructs with the different deletions and the myomegalin construct (PBP46 cDNA) were
subcloned in either pGBT9 in frame with the DNA binding domain (BD) or pGAD10 in frame with AD. These different constructs were used for
transformation of the yeast Y190 strain using the lithium acetate method (see “Experimental Procedures”). Interaction was assessed by growth in
triple dropout medium and by measuring the b-galactosidase activity. A representative experiment of the three performed is reported.
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bands correspond to splicing variants of myomegalin. A 62-kDa
protein was consistently observed in rat testis (Fig. 4C) or germ
cell extracts (data not shown). These proteins were completely
insoluble in standard homogenization conditions and could be
partially solubilized from muscle only under conditions that
extract the myofibril components (Fig. 4).
Localization of Myomegalin in Cultured Cells—Because of
the tight binding of myomegalin to particulate structures, im-
munocytochemistry was used to further analyze the localiza-
tion of this protein in transfected COS-7 cells. The truncated
form of myomegalin (PBP46; aa 1765–2324) fused to a flag
epitope was transfected in COS-7 cells and the distribution
detected with a myomegalin-specific antibody (PBP4), and with
an anti-flag antibody (Fig. 5A). An overlapping pattern of im-
munofluorescence was obtained with both antibodies confirm-
ing the specificity of the PBP4 antiserum for immunofluores-
cence localization. Moreover, a signal with PBP4 was found in
cells negative for the flag antibody, indicating the presence of
endogenous myomegalin in COS-7 cells. This expression in
COS-7 cells was confirmed by detection of myomegalin tran-
scripts by PCR amplification (data not shown). The endogenous
myomegalin localized in an inner Golgi/centrosome region that
corresponds to the location of the transfected myomegalin. To
further define the site of myomegalin localization in these cells,
centrosomal and Golgi markers were used to demonstrate an
overlapping localization with the two markers (Fig. 5, B and C).
Similar localization of myomegalin was also observed in cul-
tured FRTL-5 thyroid cells (data not shown). In these latter
cells, PDE4D is localized predominantly in a similar Golgi/
centrosomal region (16).
Colocalization of Myomegalin and PDE4D in Muscle Cells
and Testis—Because myomegalin transcripts are highly ex-
FIG. 2. Structure of myomegalin. A
diagram of the structure of myomegalin is
reported in panel A. The regions of homol-
ogy with the Drosophila centrosomin
(droCENT) dynactin (HumDYNAC), bo-
vine DAP-150 (Bov DAP-150), and Clip-
170 (HumCLIP-170) are highlighted to-
gether with the alignment of the
homologous regions. Identical residues
are in black, while conservative substitu-
tions are in gray. B, deduced amino acid
sequence of myomegalin. The gray arrow
in the sequence indicates the beginning of
the PBP46 clone. The gray box corre-
sponds to the sequence of the peptide
used to generate the PBP4 antibody. The
coiled-coil regions were identified using
the Garnier program. The uncharged do-
main contains a potential Src homology 3
binding domain.
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pressed in heart and skeletal muscle, myomegalin and PDE4D
localization was assessed in sections of cardiac (not shown) and
skeletal muscle (Fig. 6). Staining with the PBP4 antibody
yielded a periodic pattern (;2 mm) of myomegalin localization
along muscle fibrils in skeletal (Fig. 6) and cardiac (data not
shown) tissues. Double staining using a myomegalin-specific
antibody (PBP4) and a PDE4D-specific antibody (M3S1) indi-
cated colocalization of both proteins in the same region of the
myofibers (Fig. 6). This region corresponds to the z band on the
basis of a comparison with the staining of the fibers with
myosin, actin, and desmin antibodies (data not shown).
In testis, myomegalin immunoreactivity was mostly present
in germ cells of the seminiferous tubules. The antibody stained
a region in close proximity to the nucleus, corresponding to the
Golgi complex of pachytene spermatocytes and round sperma-
tids (Fig. 7). This predominant expression of the short myo-
megalin variant in germ cells was confirmed by PCR analysis,
Northern blot, and Western blot of extracts from either semi-
niferous tubules or isolated germ cells (data not shown).
Myomegalin and PDE4D3 Subcellular Localization in the
Intact Cell—Solubilization of the full-length myomegalin could
not be achieved under nondenaturing conditions. However, the
truncated myomegalin (PBP46), even though particulate after
overexpression, could be partially solubilized with RIPA buffer
containing 0.1% SDS. To determine whether this myomegalin
variant interacts with PDE4D, expression vectors for PDE4D3
and the truncated myomegalin (PBP46) were cotransfected in
COS-7 cells. Cells were solubilized with RIPA and the extract
subjected to immunoprecipitation with PDE4D-selective anti-
bodies. Under these conditions, the PDE4D-selective antibody
coimmunoprecipitated the truncated myomegalin in complex
with the PDE (Fig. 8B). The immunoprecipitation was specific
because, in the absence of PDE4D3, no myomegalin was recov-
ered in the immunoprecipitate even after overexposure of the
film (data not shown). Moreover, no myomegalin or PDE was
immunoprecipitated when unrelated IgG was used in this as-
say (data not shown). Myomegalin was recovered in the immu-
noprecipitation pellet when PDE4D1 and PDE4D3 were used
for transfection, but not with the PDE4D2 variant, which lacks
the putative domain interacting with myomegalin (Fig. 8C).
This latter finding indicates that not all PDE variants interact
with this myomegalin form.
To further confirm the interaction between the two proteins
in intact cells, expression vectors for PDE4D3 and PBP46 were
cotransfected in COS-7 cells. After 24 h the cells were homog-
enized, the particulate fraction separated by centrifugation,
and the PDE activity recovered in this fraction of the homoge-
nate was measured. Cotransfection of PDE4D3 and PBP46 led
to a 2–4-fold increase in the PDE activity recovered in the
particulate fraction (Fig. 9A) as compared with the cells trans-
fected with PDE4D3 alone. Western blot analysis with PDE4D-
specific antibodies confirmed the PDE activity data. Although
the 93-kDa PDE4D3 was at the limit of detection in the par-
ticulate fraction of COS-7 cells transfected only with PDE4D3,
cotransfection with myomegalin produced an increase in the
PDE4D3 protein recovered in the particulate fraction (Fig. 9B).
In agreement with previous observations, the short myomega-
lin variant was recovered almost exclusively in the particulate
fraction of COS-7 cells (Fig. 9C).
DISCUSSION
With these studies, we report the identification and the
initial characterization of myomegalin, a novel protein with the
properties of a structural/scaffold protein. At least three poten-
tial splicing variants of myomegalin detected in rat may serve
distinct functions in muscle and nonmuscle cells. Myomegalin
is targeted to the Golgi/centrosomal region in cultured COS-7
and FRTL-5 cells and in germ cells of the testis, whereas in
cardiac and skeletal muscle it is associated with the sarcomere
or the sarcoplasmic reticulum. We propose that one of the
functions of this protein is in cAMP signaling compartmental-
ization because it targets a PDE component of the cAMP sig-
naling to these subcellular structures.
Myomegalin is structurally related to the Drosophila centro-
somin (cnn). Centrosomin was originally identified while
screening for genes regulated by antennapedia or other ho-
meotic genes (26) and is mostly composed of coiled-coil struc-
tures with three leucine zipper domains. The first leucine zip-
per near the amino terminus is very similar to the only leucine
zipper found in one variant of myomegalin. The extensive ar-
rangement in coiled-coil structures is also shared between cen-
trosomin and myomegalin. The Drosophila centrosomin is a
component of the centrosomes and the mitotic spindle (30) and
is thought to play a crucial role during morphogenesis of the
central nervous system and midgut (26). A testis-specific iso-
form of centrosomin has been described in fly (31). Mutations
that disrupt the spermatogenic-specific centrosomin impair cy-
tokinesis, kariokinesis, and organization of the sperm axon-
eme. In a strikingly similar fashion, a splicing variant of the
mammalian myomegalin is expressed in germ cells of rat testis
and is localized in a Golgi/centrosomal region of pachytene
spermatocytes and round spermatids; however, it could not
conclusively be determined whether it is located in the basal
FIG. 3. Identification of the different myomegalin variants and
their tissue distribution. A, schematic representation of the splicing
boundary in the myomegalin sequence, the probes used for Northern
blot analysis, and the PCR primers used. B and C, Northern blot
analysis of different rat tissues using probes at the 39 end (probe 1) and
the 59 end (probe 2) of myomegalin mRNA. He, heart; Br, brain; Sp,
spleen; Lu, lung; Li, liver; Sk, skeletal muscle; Ki, kidney; Te, testis.
Exposure time was 17–20 h. D and E, RT-PCR analysis of the expres-
sion of the two long variants of myomegalin. RT-PCR was performed
with the pair of primers reported above the lanes. In some reactions, the
reverse transcriptase was omitted as a negative control (2RT). The
identity of the products was confirmed by sequencing.
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FIG. 5. Subcellular localization of
endogenous and recombinant myo-
megalin in COS-7 cells. A, COS-7 cells
were transfected with the pCEPflag-
PBP46 construct. Twenty-four h after
transfection, cells were stained with the
myomegalin-specific antibodies (PBP4) or
with the flag epitope antibodies. Fluores-
cein isothiocyanate-conjugated anti-rab-
bit secondary antibodies (green) and rho-
damine-conjugated anti-mouse IgG
secondary antibodies (red) were used to
detect the PBP4 and the monoclonal flag
antibody, respectively. Pictures were cap-
tured with a confocal microscope and
merged. B, immunofluorescence staining
of untransfected COS-7 cells with the cen-
trosomal marker CTR453 and with PBP4
antibody. C, immunofluorescence stain-
ing of untransfected COS-7 cells with the
PBP4 antibody and with the Golgi marker
CTR433.
FIG. 4. Western blot analysis of myomegalin expression using the PBP4 antibody. A, COS-7 cells were transfected with a pCEPflag-
PBP46 construct or with empty vector (mock). After 24 h, cells were harvested in homogenization buffer and the extract centrifuged at 14,000 3
g for 30 min. Pellets (P) and supernatant (S) were fractionated on SDS-PAGE, and the migration of the recombinant myomegalin was monitored
using anti-flag antibodies. B, rat heart and skeletal muscle tissue was homogenized according to the procedure detailed under “Experimental
Procedures.” Pellets and supernatants were fractionated on SDS-PAGE. After transfer, membranes were probed with the PBP4 antibody. C, total
testis (TT) or seminiferous tubules (ST) were homogenized and aliquots of the homogenates fractionated on SDS-PAGE. After transfer, the
membrane was probed with the PBP4 antibody.
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body of the developing flagellum. Thus, it is likely that the
mammalian myomegalin has functions during spermatogene-
sis that overlap with those of the centrosomin in Drosophila.
It should be pointed out that other mammalian proteins
homologous to the Drosophila centrosomin have been described
previously. These include mouse centrosomin A and B and
human 167 protein (32–34). However, their similarity to the
Drosophila centrosomin protein is low, and myomegalin is
more related to centrosomin than to these mammalian centro-
somins. The function of mammalian centrosomin is at present
unknown.
Recently, several large coiled-coil proteins localized in the
Golgi apparatus have been classified as a distinct golgin family
of proteins (35–37). Among the many members identified, gol-
gin-230/245/256, golgin 97, GM130, and giantin proteins have
extensive coiled-coil structure and a domain at the carboxyl
terminus that specifies Golgi targeting (grip domain). Myo-
megalin is weakly homologous to golgin 230/245/256 (20% iden-
tity, 40% conservative substitutions) in several coiled-coil do-
mains. However, a domain similar to the grip domain could not
be identified at the carboxyl terminus of myomegalin, even
though the last 550 amino acids of this latter protein are
sufficient to target it to the Golgi/centrosome structures.
Although formal proof of an interaction of PDE4D with the
full-length myomegalin was precluded by the insolubility of the
protein, we have provided evidence of an interaction of the
62–64-kDa myomegalin variant with PDE4D. Four independ-
ent lines of evidence indicate that the two proteins may indeed
exist in a complex in the intact cell. In addition to the interac-
tion detected with the yeast two-hybrid screening, the 64-kDa
variant of myomegalin and PDE4D interact specifically in a
coimmunoprecipitation assay. Furthermore, cotransfection of
FIG. 6. Colocalization of myomegalin and PDE4D in mouse skeletal muscle. Sections of mouse skeletal muscle were stained with
myomegalin (PBP4, red) and PDE4D-specific (M3S1, green) antibodies. The distance between the two contiguous bands was estimated to be 2 mm,
consistent with the length of a sarcomere. The staining with myomegalin and PDE4D antibodies overlapped with that of desmin but not with either
myosin or actin. The periodic pattern of PDE4D staining was confirmed by a second polyclonal anti-PDE4 antibody. In all instances, staining could
be blocked by preadsorption of the primary antibody with the corresponding peptide or fusion protein. Similar results were obtained with rat
skeletal muscle.
FIG. 7. Cellular localization of testis-specific myomegalin in
germ cells. Sections of adult rat testis were stained with the myomega-
lin antibody (PBP4) in the absence or presence of peptide PBP4. DAPI
was used to stain the nuclei of developing germ cells and somatic cells.
FIG. 8. Coimmunoprecipitation of myomegalin and PDE4D3.
A, diagram of the domains present in the three PDE4D variants used
for the coimmunoprecipitation. B, COS cells were transfected with
either a PDE4D (pCMV5-PDE4D3) or a myomegalin (pCEP4-PBP46)
expression vector or a combination of the two. After homogenization
and centrifugation, the supernatant and the RIPA-extracted superna-
tant were combined and subjected to immunoprecipitation with
PDE4D-selective monoclonal antibodies. The pellets of the immunopre-
cipitation or an aliquot of the supernatant before precipitation were
analyzed by SDS-PAGE and Western blot using either myomegalin-
(PBP4) or PDE4D-selective (M3S1) antibodies. When immunoprecipi-
tation was carried out with nonimmune IgG as a control, neither
PDE4D3 nor myomegalin were recovered in the pellet (data not shown).
C, COS cells were cotransfected with vectors containing PDE4D1,
PDE4D2, or PDE4D3 cDNAs and a myomegalin expression plasmid
(pCEP4-PBP46). After 24 h, cell extracts were prepared and processed
for immunoprecipitation and Western blot analyses as reported for
panel B.
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myomegalin targeted the recombinant PDE4D3 to the partic-
ulate fraction of COS-7 cells. Finally, myomegalin and PDE4D
were colocalized in cultured cells as well as in cardiac and
skeletal muscle tissue.
Deletion mutagenesis of PDE4D indicates that a site of in-
teraction with myomegalin is in a domain that corresponds to
the amino terminus of the upstream conserved region 2
(UCR2). This domain is conserved in all the long forms of PDE4
opening the possibility that other PDE4s may interact with
myomegalin. This interacting domain of PDE4D consists of a
region of predicted a-helical structure with amphipathic distri-
bution of the charges. The carboxyl terminus of myomegalin
also contains a-helical domains that may mediate the interac-
tion with a PDE. Using the yeast two-hybrid assay, we have
reported that this PDE4D domain, which interacts with myo-
megalin, is also involved in intramolecular interactions with
the amino-terminal regulatory domain and that it functions as
an autoinhibitory domain that modulates the catalytic activity
of the enzyme (18). At present, it is not clear whether the
intramolecular interaction and the binding to myomegalin are
mutually exclusive or if they can occur at the same time, nor is
it known whether the binding of myomegalin alters the cata-
lytic activity of the PDE. We have reported that phosphoryla-
tion of PDE4D3 alters the interaction of this domain with the
amino terminus (18); it is then possible that the state of phos-
phorylation also affects the ability of the PDE4D to interact
with myomegalin. Further studies are required to clarify this
issue. It is possible that the interaction of PDE4D with myo-
megalin, and therefore with the Golgi/centrosome, may be a
dynamic process and that translocation of this protein may
occur during signaling. Indeed, data have recently been re-
ported indicating that PDE4D3 may translocate upon activa-
tion of the mitogen-activated protein kinase pathway (38).
In view of its extensive coiled-coil composition, it is likely
that myomegalin either oligomerizes with itself or interacts
with other proteins. The presence of a leucine zipper domain,
which is also known to mediate protein/protein interaction, is
consistent with this conclusion. In addition to a PDE, other
proteins may be interacting with myomegalin. Using homology
searches, a domain similar to the domain involved in dynactin-
centractin interaction, a helix-loop-helix found in Clip170, and
an uncharged domain that resembles an Src homology 3 bind-
ing domain, were identified. Thus, the presence of these puta-
tive interacting domains suggests that myomegalin is present
in a complex with several additional proteins, which may be
involved in vesicle transport or with their interaction with
cytoskeletal structures. This raises the possibility that myo-
megalin may play a role in vesicle transport between the dif-
ferent layers of the Golgi stack.
Myomegalin is expressed at high levels in skeletal and car-
diac tissue, suggesting an important function in muscle cells.
Upon staining with a myomegalin antibody, a periodic pattern
was observed indicating localization either in the z region be-
tween sarcomeres or in the sarcoplasmic reticulum. It could not
be determined whether PDE4D and myomegalin are in the z
band proper or are associated with the sarcoplasmic reticulum.
Several other cAMP-signal transduction proteins have been
localized in the same region of the sarcomere including adeny-
lyl cyclase, L channels, and the regulatory subunit of PKA (39,
40). Thus, it is plausible that myomegalin brings PDE4D to a
site where several steps in the cAMP signaling cascade take
place in muscle cells.
The colocalization of PDE4D and myomegalin in Golgi/cen-
trosomal structures points to a role of cyclic nucleotide signal-
ing in the function of these organelles. Targeting of a PDE to
the Golgi may have an important function in controlling cAMP
diffusion to these regions. Interestingly, PKA regulatory sub-
units, and anchoring AKAPs, have also been localized in the
Golgi apparatus and in the centrosome (8, 9, 41, 42). Thus, our
findings suggest that PDE4D localization in these regions
serves to control the state of activation of PKAs and therefore
the cAMP-regulated phosphorylations in these domains. The
exact role of cAMP signaling in centrosome function and in
vesicle transport in the Golgi is largely unknown, even though
there is ample indirect evidence that cAMP regulates both
cytoskeleton assembly as well as vesicle transport (43, 44).
Pigment granule redistribution in Xenopus melanocytes is reg-
ulated by cAMP (45), and cyclic nucleotides have long been
implicated in the control of flagellar movements (46). Thus, it is
possible that strategic localization of a PDE in these regions via
myomegalin interaction may be involved in the control of or-
ganelle movements or cytoskeletal assembly/disassembly.
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